Learn how generic drug makers use Paragraph IV certifications to challenge brand patents under the Hatch-Waxman Act. Discover the 180-day exclusivity rule, the 30-month stay, and the economic impact on drug prices.
An ANDA, or Abbreviated New Drug Application, is the FDA pathway that allows generic drugs to enter the market without repeating costly clinical trials. It ensures generics are as safe and effective as brand-name drugs, saving billions annually.
Learn exactly what the FDA requires for stability testing of generic drugs, including batch sizes, testing conditions, timelines, and common reasons for approval delays. Understand why this process ensures your medication stays safe and effective.